Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to test:

1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.


Options:
A: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: brentuximab vedotin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: brentuximab vedotin; Assigned to Arm(s): Brentuximab vedotin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: BEACOPP escalated | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: BEACOPP escalated; Assigned to Arm(s): A, B, C, D
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Involved Field Radiotherapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Other: No further treatment | Intervention Type: RADIATION; Name: Involved Field Radiotherapy; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: No further treatment; Assigned to Arm(s): Arm II

Answer: C